Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.
Identifieur interne : 001419 ( Main/Corpus ); précédent : 001418; suivant : 001420Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.
Auteurs : Pierluigi Viale ; Michele BartolettiSource :
- Le infezioni in medicina [ 1124-9390 ] ; 2020.
English descriptors
- KwdEn :
- Aged (MeSH), Anti-Inflammatory Agents (pharmacology), Anti-Inflammatory Agents (therapeutic use), Anticoagulants (pharmacology), Anticoagulants (therapeutic use), Antihypertensive Agents (therapeutic use), Azithromycin (administration & dosage), Azithromycin (therapeutic use), COVID-19 (MeSH), Combined Modality Therapy (MeSH), Coronavirus Infections (complications), Coronavirus Infections (diagnostic imaging), Coronavirus Infections (drug therapy), Coronavirus Infections (therapy), Drug Therapy, Combination (MeSH), Enoxaparin (pharmacology), Enoxaparin (therapeutic use), Humans (MeSH), Hydroxychloroquine (administration & dosage), Hydroxychloroquine (therapeutic use), Hypertension (complications), Hypertension (drug therapy), Male (MeSH), Oxygen Inhalation Therapy (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (diagnostic imaging), Pneumonia, Viral (drug therapy), Pneumonia, Viral (therapy), Thrombophilia (drug therapy), Thrombophilia (etiology), Tomography, X-Ray Computed (MeSH), Valsartan (therapeutic use).
- MESH :
- chemical , administration & dosage : Azithromycin, Hydroxychloroquine.
- chemical , pharmacology : Anti-Inflammatory Agents, Anticoagulants, Enoxaparin.
- chemical , therapeutic use : Anti-Inflammatory Agents, Anticoagulants, Antihypertensive Agents, Azithromycin, Enoxaparin, Hydroxychloroquine, Valsartan.
- complications : Coronavirus Infections, Hypertension, Pneumonia, Viral.
- diagnostic imaging : Coronavirus Infections, Pneumonia, Viral.
- drug therapy : Coronavirus Infections, Hypertension, Pneumonia, Viral, Thrombophilia.
- etiology : Thrombophilia.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Aged, COVID-19, Combined Modality Therapy, Drug Therapy, Combination, Humans, Male, Oxygen Inhalation Therapy, Pandemics, Tomography, X-Ray Computed.
Abstract
A 71-year old gentleman with history of arterial hypertension treated with valsartan presented on was hospitalized at the Infectious Diseases Unit, University of Bologna (Italy) for severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) and received treatment with hydroxychloroquine 200mg bid (400 mg bid the first day), azithromycin 400 mg qd, thrombotic prophylaxis with enoxaparin 4000 UI qd and Venturi mask oxygen delivering FiO2 of 31%. The case highlights the high frequency of coagulopathy in patients with moderate to severe cases of SARS-CoV-2 associated disease (COVID-19). After one week the patient significantly improved and the daily dose of enoxaparin was reduced and definitively discontinued four days later. The case highlights the high frequency of coagulopathy in patients with moderate to severe cases of SARS-CoV-2 associated disease (COVID-19). Considering the available information we believe that LMWH may represent a promising treatment for COVID-19 but further well-designed trials are needed to address these points.
PubMed: 32532948
Links to Exploration step
pubmed:32532948Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.</title><author><name sortKey="Viale, Pierluigi" sort="Viale, Pierluigi" uniqKey="Viale P" first="Pierluigi" last="Viale">Pierluigi Viale</name><affiliation><nlm:affiliation>Dipartimento di Scienze Mediche e Chirurgiche, Alma Mater Studiorum Università di Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bartoletti, Michele" sort="Bartoletti, Michele" uniqKey="Bartoletti M" first="Michele" last="Bartoletti">Michele Bartoletti</name><affiliation><nlm:affiliation>Dipartimento di Scienze Mediche e Chirurgiche , Alma Mater Studiorum Università di Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32532948</idno><idno type="pmid">32532948</idno><idno type="wicri:Area/Main/Corpus">001419</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001419</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.</title><author><name sortKey="Viale, Pierluigi" sort="Viale, Pierluigi" uniqKey="Viale P" first="Pierluigi" last="Viale">Pierluigi Viale</name><affiliation><nlm:affiliation>Dipartimento di Scienze Mediche e Chirurgiche, Alma Mater Studiorum Università di Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bartoletti, Michele" sort="Bartoletti, Michele" uniqKey="Bartoletti M" first="Michele" last="Bartoletti">Michele Bartoletti</name><affiliation><nlm:affiliation>Dipartimento di Scienze Mediche e Chirurgiche , Alma Mater Studiorum Università di Bologna, Bologna, Italy.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Le infezioni in medicina</title><idno type="ISSN">1124-9390</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Anti-Inflammatory Agents (pharmacology)</term><term>Anti-Inflammatory Agents (therapeutic use)</term><term>Anticoagulants (pharmacology)</term><term>Anticoagulants (therapeutic use)</term><term>Antihypertensive Agents (therapeutic use)</term><term>Azithromycin (administration & dosage)</term><term>Azithromycin (therapeutic use)</term><term>COVID-19 (MeSH)</term><term>Combined Modality Therapy (MeSH)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (diagnostic imaging)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (therapy)</term><term>Drug Therapy, Combination (MeSH)</term><term>Enoxaparin (pharmacology)</term><term>Enoxaparin (therapeutic use)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (administration & dosage)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Hypertension (complications)</term><term>Hypertension (drug therapy)</term><term>Male (MeSH)</term><term>Oxygen Inhalation Therapy (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (diagnostic imaging)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (therapy)</term><term>Thrombophilia (drug therapy)</term><term>Thrombophilia (etiology)</term><term>Tomography, X-Ray Computed (MeSH)</term><term>Valsartan (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Azithromycin</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Anticoagulants</term><term>Enoxaparin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Inflammatory Agents</term><term>Anticoagulants</term><term>Antihypertensive Agents</term><term>Azithromycin</term><term>Enoxaparin</term><term>Hydroxychloroquine</term><term>Valsartan</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Hypertension</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Hypertension</term><term>Pneumonia, Viral</term><term>Thrombophilia</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Thrombophilia</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>COVID-19</term><term>Combined Modality Therapy</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Male</term><term>Oxygen Inhalation Therapy</term><term>Pandemics</term><term>Tomography, X-Ray Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A 71-year old gentleman with history of arterial hypertension treated with valsartan presented on was hospitalized at the Infectious Diseases Unit, University of Bologna (Italy) for severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) and received treatment with hydroxychloroquine 200mg bid (400 mg bid the first day), azithromycin 400 mg qd, thrombotic prophylaxis with enoxaparin 4000 UI qd and Venturi mask oxygen delivering FiO2 of 31%. The case highlights the high frequency of coagulopathy in patients with moderate to severe cases of SARS-CoV-2 associated disease (COVID-19). After one week the patient significantly improved and the daily dose of enoxaparin was reduced and definitively discontinued four days later. The case highlights the high frequency of coagulopathy in patients with moderate to severe cases of SARS-CoV-2 associated disease (COVID-19). Considering the available information we believe that LMWH may represent a promising treatment for COVID-19 but further well-designed trials are needed to address these points.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32532948</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1124-9390</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>suppl 1</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>Le infezioni in medicina</Title><ISOAbbreviation>Infez Med</ISOAbbreviation></Journal><ArticleTitle>Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.</ArticleTitle><Pagination><MedlinePgn>118-121</MedlinePgn></Pagination><Abstract><AbstractText>A 71-year old gentleman with history of arterial hypertension treated with valsartan presented on was hospitalized at the Infectious Diseases Unit, University of Bologna (Italy) for severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) and received treatment with hydroxychloroquine 200mg bid (400 mg bid the first day), azithromycin 400 mg qd, thrombotic prophylaxis with enoxaparin 4000 UI qd and Venturi mask oxygen delivering FiO2 of 31%. The case highlights the high frequency of coagulopathy in patients with moderate to severe cases of SARS-CoV-2 associated disease (COVID-19). After one week the patient significantly improved and the daily dose of enoxaparin was reduced and definitively discontinued four days later. The case highlights the high frequency of coagulopathy in patients with moderate to severe cases of SARS-CoV-2 associated disease (COVID-19). Considering the available information we believe that LMWH may represent a promising treatment for COVID-19 but further well-designed trials are needed to address these points.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Viale</LastName><ForeName>Pierluigi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Mediche e Chirurgiche, Alma Mater Studiorum Università di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bartoletti</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Dipartimento di Scienze Mediche e Chirurgiche , Alma Mater Studiorum Università di Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Infez Med</MedlineTA><NlmUniqueID>9613961</NlmUniqueID><ISSNLinking>1124-9390</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>80M03YXJ7I</RegistryNumber><NameOfSubstance UI="D000068756">Valsartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019851" MajorTopicYN="N">Thrombophilia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068756" MajorTopicYN="N">Valsartan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32532948</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001419 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001419 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32532948
|texte= Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32532948" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |